Loading data for NEO — first visit, this takes a few seconds.

Preisalarm

NeoGenomics Inc. (NEO)

NasdaqCM: NEO · Echtzeitkurs · USD

16.53

-0.13 (-0.78%)

Zum Schluss: Aug 21, 2026, 8:00 PM

17.08

+0.59%

Nachbörslich: 4:54 PM

Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.

-0.78% (1D)

Keine Daten verfügbar

Geld	11.97
Marktkapitalisierung	2.18 Mrd
Umsatz (TTM)	766.29 Mio
Nettogewinn (TTM)	-51.88 Mio
	1.73
	-0.39
	n/a
	49.41
KBV (TTM)	2.76
KUV (TTM)	2.89
Termin Quartalszahlen	Apr 29, 2025

Brief	20.49
Volumen	2,748,077
Ø Vol. (20D)	2,771,100
Eröffnung	15.98
Vortagesschluss	16.66
Tagesspanne	15.98 - 16.81
52-Wk Range	5.94 - 16.92
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...

[Mehr lesen]

Branche Diagnostics & Research

Sektor Healthcare

IPO Datum Mar 16, 2004

Mitarbeiter 2,500

Börse NasdaqCM

Tickersymbol NEO

Website https://www.neogenomics.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von NeoGenomics 727.33 Mio, ein Anstieg von 10.11% im Vergleich zum Vorjahr (660.57 Mio). Der Gewinn lag bei -108.03 Mio, ein Anstieg von 37.22 %.

Finanzberichte

Gewinnüberraschung

NeoGenomics hat die Quartalszahlen am Jul 28, 2026 veröffentlicht:

Umsatz von $201.66 Mio verfehlt die Erwartungen um $0, mit 11.21% Wachstum im Jahresvergleich.

EPS von 0.05 übertrifft die Erwartungen um 0.02, mit 66.67% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

NeoGenomics Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Apr 29, 2025, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 1 Woche · StockStory

3 Stocks Under $50 with Open Questions

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some ...

vor 2 Wochen · Simply Wall St.

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss o...

vor 2 Wochen · Zacks

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

vor 2 Wochen · Simply Wall St.

NeoGenomics (NEO) Following Q2 Profit And Raised Outlook, Is Fair Value Already Priced In?

NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expe...

vor 2 Wochen · StockStory

3 Healthcare Stocks with Questionable Fundamentals

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance bu...

Seite 1 von 2

NeoGenomics Inc. (NEO)